MATH+®

COVID HOSPITAL TREATMENT

A GUIDE TO MANAGING THE HOSPITALIZED COVID-19 PATIENT

September 6, 2022

FLCCC ALLIANCE

Table of Contents

Disclaimer

The information in this document is our recommended approach to COVID-19 in the hospitalized patient, based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the prevention and early treatment of COVID-19. Our guidance should only be used by medical professionals in formulating their approach to COVID-19. Patients should always consult with their provider before starting any medical treatment. As this is a highly dynamic topic, we will update these guidelines as new information emerges. Please ensure you are using the latest version of this protocol.

To read more about the safety of the vitamins and nutraceuticals listed on the FLCCC protocols during pregnancy, please review this document.

The Use of "Off-Label" Drugs

Once the FDA approves a prescription medication, federal laws allow any U.S. physician to prescribe the duly approved drug for any reason. [1] In fact, 30 percent of all prescriptions are for off-label uses, written by American doctors exercising their medical judgment.

Many states — including Nebraska, Tennessee, and Missouri — have asserted the right of physicians to prescribe, and pharmacists to dispense, off-label drugs such as ivermectin and hydroxychloroquine for the treatment of COVID-19. For example, Nebraska's Attorney General, Doug Peterson, released a legal opinion in October 2021 saying he did not see data to justify legal action against healthcare professionals who prescribe ivermectin or hydroxychloroquine. [2] In May 2022, Tennessee approved a standing order allowing ivermectin to be dispensed over the counter.

Overview of MATH+ and Key Concepts

As the pandemic has played out over the last two years, more than six million patients have died worldwide. Most countries across the globe have limited resources to manage this humanitarian crisis. The FLCCC physicians developed the **MATH+ protocol** to provide guidance for the treatment of the pulmonary phase of this devastating disease with the goal of reducing hospital mortality. We are now realizing the relentless malpractice of deliberately withholding effective early COVID treatments and forcing the use of toxic remdesivir in hospitalized patients may have unnecessarily killed up to 800,000 Americans. [3]

The core principle of MATH+ is the use of anti-inflammatory agents to dampen the "cytokine storms," together with anticoagulation to limit the microvascular and macrovascular clotting, and supplemental oxygen to help overcome the hypoxia.

COVID is an extraordinarily complex, yet treatable, disease; many of its mysteries are still unravelling. However, a few concepts are key to its management.

It is critically important to recognize that infection with SARS-CoV-2, the virus that causes COVID-19, progresses through stages. Treatment approaches are therefore highly stage-specific (see Figures 2-4 and Table 1). Antiviral therapy is likely to be effective only during the viral replicative phase. Anti-inflammatory therapy is expected to be effective during the pulmonary phase and possibly the post-COVID phase.

While there is no "magic bullet" for COVID-19, several therapeutic agents have shown great promise for the treatment of this disease. These include ivermectin, Vitamin D, quercetin, melatonin, fluvoxamine, spironolactone, corticosteroids, curcumin (turmeric), *Nigella sativa* and anti-androgen therapy. A growing body of evidence suggests that many of these agents may act synergistically in various phases of the disease. [4-6] In the midst of a global pandemic, the use of cheap, effective, and safe repurposed drugs has and will continue to have a major role to play. We must focus on the totality of evidence, and not just on randomized controlled trials (RCTs) (see Figure 1).

Ivermectin has emerged as a highly effective drug for the prophylaxis and treatment of COVID-19. Ivermectin inhibits viral replication and has potent anti-inflammatory properties. Emerging data (including RCTs) suggest that ivermectin may have an important clinical benefit across the spectrum of phases of the disease, i.e., pre-exposure prophylaxis, post-exposure prophylaxis, during the symptomatic phase and during the pulmonary phase. [7-29] In the recommended dosages, ivermectin is remarkably safe and effective against SARS-CoV-2. However, as noted below, there is the potential for serious drug-drug interaction.

COVID-19 is essentially a clinical diagnosis supported by laboratory tests. At symptom onset, a PCR test will be positive in approximately 60% of patients; maximal positivity rate is on day 8 (post-infection) when 80% of patients will be positive (see Figure 4). [30] A PCR test remains positive for at least two weeks. Patients who progress to the pulmonary phase are usually PCR-positive, despite cessation of viral replication (and are therefore less likely to be infectious). However, due to the imperfect sensitivity of the PCR test, as many as 20% of patients who progress to the pulmonary phase will be PCR-negative (even on repeat testing).

Symptomatic patients are likely to be infectious during a narrow window starting 2–3 days before the onset of symptoms and to up to 6 days after the onset of symptoms (see Figure 4). [31]

COVID-19 patients present with a variety of phenotypes, likely dependent on inoculum size and viral load, virus variant, genetic heterogeneity mutations and polymorphisms, biotypes, blood type, sex and androgen status, age, race, BMI (obesity), immunological and nutritional status, and comorbidities. [32-43] The phenotype at presentation determines the prognosis and impacts the optimal approach to treatment. It is noteworthy that obesity and increasing BMI are critical prognostic factors. This may be related to the fact that there are more ACE-2 receptors in visceral fat than in the lung. [44]

The pulmonary phase is characterized by prolonged immune dysregulation, [35;45-59] a pulmonary microvascular injury (vasculopathy), [58-62] with activation of clotting and a procoagulant state together with the characteristics of an organizing pneumonia. [63;64] Immune dysregulation may last weeks or even months. The early and abrupt termination of anti-inflammatory agents will likely result in rebound inflammation. [65]

Endothelial damage and an imbalance of both innate and adaptive immune responses, with aberrant macrophage activation, plays a central role in the pathogenesis of the severe COVID-19 disease. [59]

The pulmonary phase of COVID-19 is a treatable disease; it is inappropriate to limit therapy to "supportive care" alone. As patients progress down the pulmonary cascade the disease becomes more difficult to reverse. The implications of this are two-fold:

- Early treatment of the pulmonary phase is ESSENTIAL to a good outcome.

- Treatment in the late pulmonary phase may require escalation of the dose of corticosteroids as well as the use of salvage methods (i.e., plasma exchange). However, patients who present in the late pulmonary phase may have progressed to the irreversible pulmonary fibroproliferative phase.

The radiographic and pathological findings of COVID-19 lung disease are characteristic of a Secondary Organizing Pneumonia (and not ARDS). [63;66;67] The initial pulmonary phase neither looks like, smells like nor is ARDS. [68-70] The ground glass infiltrates are peripheral and patchy, [66] and do not resemble the dependent air space consolidation (sponge/baby lung) seen with "typical ARDS". [71] Extravascular lung water index (EVLWI) is normal or only slightly increased; this, by definition, excludes non-cardiogenic pulmonary edema (ARDS). Lung compliance is normal (this excludes ARDS). Patients are PEEP unresponsive. Treating patients as if they ARDS is an extremely dangerous approach. The hypoxia is due to an organizing pneumonia with severe ventilation/perfusion mismatch likely due to the microvascular narrowing, thrombosis and vasoplegia.

SARS-CoV-2, as compared to all other respiratory viruses, upregulates cytokines and chemokines while at the same time down regulating the expression of Interferon alpha (the hosts primary antiviral defense mechanism). [131,155] Low innate antiviral defenses and high pro-inflammatory mediators contribute to ongoing and progressive lung injury.

An unknown percentage of patients with COVID-19 present with "silent hypoxia" with a blunted respiratory response. This phenomenon may be related to involvement of chemoreceptors of the carotid bodies and/or brain stem dysfunction, [72;73] and necessitates pulse oximetry in symptomatic patients managed at home.

It should be recognized that Low Molecular Weight Heparin (LWMH) has non-anticoagulant properties that are likely beneficial in patients with COVID-19; these include anti-inflammatory effects and inhibition of histones. [74] In addition, in vitro studies demonstrate that heparin inhibits SARS-CoV-2 interaction with the ACE-2 receptor and viral entry, [75;76] as well as viral replication [11;77]. Most importantly LWWH inhibits heparanase (HPSE). [78] HSE destroys the endothelial glycocalyx increasing endothelial leakiness, activating clotting and potentiating endothelialitis. [78] HPSE levels have been reported to be increased in patients with severe COVID-19 infection. [79] Due to the ease of administration, greater anti-Xa activity and better safety profile, we prefer low molecular weight heparin (LMWH) to unfractionated heparin (UFH).

The combination of steroids and ascorbic acid (Vitamin C) is essential. Both have powerful synergistic anti-inflammatory actions. [80;81] Vitamin C protects the endothelium from oxidative injury. [82-85] Furthermore, Vitamin C Increases the expression of interferon-alpha [86] while corticosteroids (alone) decrease expression of this important protein. [87-90] It should be noted that when corticosteroids are used in the pulmonary phase (and not in the viral replicative phase) they do not appear to increase viral shedding or decrease the production of type specific antibodies. [91;92] It is likely that LMWH acts synergistically with corticosteroids and Vitamin C to protect the endothelium and treat the endothelialitis of severe COVID-19 disease.

Notwithstanding the particularly important and impressive results of the RECOVERY-Dexamethasone study, methylprednisolone is the corticosteroid of choice for the pulmonary phase of COVID-19. This is based on pharmacokinetic data (better lung penetration), [93] genomic data specific for SARS-CoV-2, [94] and a long track record of successful use in inflammatory lung diseases (see Table 1).

Figure 1. Evaluating the Totality of Evidence

Source: FLCCC

Figure 2. The Course of COVID-19 and General Approach to Treatment

	I. Incubation	II. Symptomatic	III. Early Pulmonary Phase	IV. Late Pulmonary Phase
Ground-glass infiltrates		+	++	+++	++++
Clinical Symptoms		Fever, malaise, cough, headache, diarrhea	SOB – Mild hypoxia ≤4 L/min N/C & aSat < 94%	Progressive hypoxia
Treatment approach		Antiviral Rx	Anti-inflammatory Rx	
Potential therapies	Hydroxychloroquine 200mg BID	Methylprednisolone 40 mg q 12 inc. to 80 - 250 mg if reqd.	
	ASA + Gargle + Nose Spray	Enoxaparin 1mg/kg q 12	Enoxaparin 60mg/day
	IVERMECTIN 0.2 -0.4 mg/kg x 2-5 doses	IVERMECTIN 0.4-0.6 mg/kg for 5 doses	
	Melatonin + Vitamin D + Vitamin C + Fluvoxamine + Flavanoid + Zinc + Omega 3's		

Source: FLCCC

Figure 3. Timing of the Initiation of Anti-Inflammatory Therapy

Source: FLCCC

**Note:** Viral replication in Figures 2 and 3 are typical for the original Wuhan SARS-CoV-2 virus (Alpha strain). The time course of Omicron BA.4 and BA.5 appears to be contracted/shortened compared to the Wuhan (Alpha) strain.

THIS IS A STEROID-RESPONSIVE DISEASE:

HOWEVER, TIMING IS CRITICAL.

Not too early. Not too late.

Figure 4. Time Course of Laboratory Tests for COVID-19

Source: FLCCC

Table 1. Pharmacological Therapy for COVID-19 by Stage of Illness: What has worked and what has failed*

	Pre-exposure/ Post-Exposure/Incubation	Symptomatic Phase	Pulmonary/ inflammatory phase
Ivermectin	BENEFIT	BENEFIT	BENEFIT
Hydroxychloroquine	Benefit**	Benefit**	?Trend to harm
Corticosteroids	n/a	Trend to harm	BENEFIT
Anti-androgen Rx	? Benefit	Benefit	BENEFIT
LMWH	n/a	n/a	BENEFIT
Paxlovid/Molnupiravir	n/a	No Benefit	n/a
Monoclonal Abs	No Benefit	No benefit	HARM
Lopivinar-Ritonavir	n/a	No benefit	No benefit
Tocilizumab	n/a	n/a	Unclear Benefit
Convalescent Serum	n/a	No benefit	Trend to harm
Colchicine	n/a	Unclear benefit	No Benefit

Source: FLCCC

** Due to extensive fraudulent activity around the design and conduct of RCTs, the benefit of HCQ is supported largely by numerous consistently positive observational trials.

Table 2. Drug Interactions with Ivermectin

Patients taking any of these medications should discuss with their treating physicians.

SERIOUS (5) Use Alternative	MONITOR CLOSELY (50)	
erdafitinib	amiodarone	lonafarnib
lasmiditan	atorvastatin	loratadine
quinidine	berotralstat	lovastatin
sotorasib	bosutinib	nefazodone
tepotinib	clarithromycin	nicardipine
	clotrimazole	nifedipine
	dronedarone	nilotinib
	elagolix	phenobarbital
	eliglustat	phenytoin
	erythromycin base	ponatinib
	erythromycin ethylsuccinate	quercetin
	erythromycin lactobionate	ranolazine
	erythromycin stearate	rifampin
	felodipine	ritonavir
	fosphenytoin	sarecycline
	fostamatinib	simvastatin
	glecaprevir/pibrentasvir	sirolimus
	indinavir	St John's Wort
	istradefylline	stiripentol
	itraconazole	tacrolimus
	ivacaftor	tolvaptan
	ketoconazole	trazodone
	lapatinib	tucatinib
	levoketoconazole	verapamil
	lomitapide	warfarin

Source: Medscape

Mildly Symptomatic Patients (On hospital floor/ward)

First Line Therapies (in order of priority)

Ivermectin, low molecular weight heparin (**LMWH)** and **corticosteroids** form the foundation of care for the hospitalized patient. Multiple RCTs have demonstrated that these drugs reduce the mortality of patients hospitalized with COVID-19.

- **Ivermectin** 0.4–0.6 mg/kg daily for 5 days or until symptoms resolve (see Figure 4). A higher dose may be required when treatment is delayed and in patients with more severe disease. [7-12;15-18;20;29;95-102]. Ivermectin retains full efficacy against the Omicron variants (as best we know). Ivermectin is best taken with a meal or just following a meal for greater absorption. It should be noted that ivermectin has potent anti-inflammatory properties apart from its antiviral properties. [13;14;23;103] Ivermectin is a remarkably safe drug with minimal adverse reactions (almost all minor). [29] However, potential drug-drug interactions should be reviewed before prescribing ivermectin (see Table 2). Note that ivermectin should not be administered with quercetin.

- **Methylprednisolone** 80 mg bolus dose followed by 40 mg every 12 hours (alternative: 80 mg bolus followed by 80 mg/240 ml normal saline IV infusion at 10 ml/hr); increase to 80 mg and then 125 mg every 12 hours in patients with progressive symptoms and increasing c-reactive protein (CRP). There is now overwhelming and irrefutable evidence that corticosteroids reduce the risk of death in patients in the pulmonary phase of COVID-19, i.e., those requiring supplemental oxygen or higher levels of support. [37;91;104-114] **We believe that the use of low fixed dose dexamethasone is inappropriate for the treatment of the pulmonary phase of COVID-19.** The role of inhaled corticosteroids (budesonide) is unclear and appears to be rather limited. While methylprednisolone is the corticosteroid of choice, in regions/countries where it is not available the following (in order of preference) may be substituted for methylprednisolone (dose adjusted according to methylprednisolone dosages): prednisolone; prednisone; hydrocortisone; and, LASTLY, dexamethasone.

- **Enoxaparin** 1 mg/kg every 12 hours (see dosage adjustments and Xa monitoring below). The ATTACC, ACTIV-4a & REMAP-CAP trials demonstrated a significant reduction of the primary endpoint (composite of organ support days and hospital mortality) regardless of D-dimer levels. [115]

- **Vitamin C** 500–1000 mg every 6 hours.

- **Quercetin** 250–500 mg twice daily (if available). Note that ivermectin should not be administered with quercetin.

- **Zinc** 75–100 mg/day.

- **Melatonin** 6 mg at night. [116-122]

- **Fluvoxamine** 50 mg twice daily. Fluoxetine 20-40 mg daily is an alternative. [123-126] NOTE: Some individuals who are prescribed fluvoxamine experience acute anxiety,

which needs to be carefully monitored for and treated by the prescribing clinician to prevent rare escalation to suicidal or violent behavior.

Second Line and Optional Treatments

- **Nitazoxanide (NTZ)** 600 mg twice daily for 7 days. [127] NTZ is considered an alternative to ivermectin, or part of a multi-drug combination that includes ivermectin. It should be noted that while NTZ is relatively cheap in most of the world, it is very expensive in the United States.

- **Vitamin D3/Calcifediol**. For patients hospitalized with COVID-19, the dosing scheme listed in Table 3 is suggested. Vitamin D3 requires hydroxylation in the liver to become 25(OH)D, causing a lag of about 3 to 4 days. [128] This may explain the lack of benefit of Vitamin D3 in patients hospitalized with severe COVID-19. [129] Calcifediol is already 25-hydroxylated, and thus, it bypasses the liver and become available in the circulation within four hours of administration. Among other benefits, it permits boosting the immune system and improving the functions of other systems within a day. Orally administered, a single dose of calcifediol raises serum 25(OH)D concentration within four hours. Therefore, calcifediol is particularly useful in acute infections like COVID-19, and in sepsis. [130-134] The single oral calcifediol dose is calculated as 0.014 mg/kg body weight. To be most effective, a loading dose of Vitamin D3 should be administered with or within the first week of administration of calcifediol. We recommend against the use of **calcitriol** [1,25(OH)2D], which has minimal effect on immune cells. Moreover, the effective dose (ED50) and toxic level overlap at the dose currently suggested for COVID-19. [135]

- **Aspirin/Acetylsalicylic acid (ASA)** 325 mg daily — if not contraindicated. Moderate to severe COVID infection results in profound platelet activation, contributing to the pro-thrombotic state and increasing the inflammatory response. [136-139]

- **B complex** vitamins.

- **N-acetyl cysteine (NAC)** 600-1200 mg by mouth twice daily. [140-144]

- **Anti-androgen therapy** (both men and women). Spironolactone 100 mg twice daily for 10 days. Second line anti-androgen: Dutasteride 2 mg day 1, followed by 1 mg for 10 days. AVOID IN PREGNANCY. [145-147]

- *Optional:* **Famotidine** 40 mg twice daily (20–40 mg/day in renal impairment). [148-154] Famotidine may be useful for its protective effect on gastric mucosa, as well as its antiviral and histamine-blocking properties.

- *Optional:* The anti-serotonin agent, **cyproheptadine** 4–8 mg by mouth every 6 hours should be considered in patients with more severe disease. [155;156] Patients with COVID-19 have increased circulating levels of serotonin, which is likely the result of increased platelet activation and decreased removal by the pulmonary circulation due to an extensive microcirculatory vasculopathy. [155;157-159] Increased circulating serotonin is associated with pulmonary, renal, and cerebral vasoconstriction and may partly explain the V/Q mismatch and reduced renal blood flow noted in patients with severe COVID-19 infection. [160-163] Furthermore, serotonin itself enhances platelet

aggregation, creating a propagating immuno-thrombotic cycle. [164] In addition, serotonin receptor blockade may reduce progression to pulmonary fibrosis. [165]

- *Optional*: **Vascepa** (Ethyl eicosapentaenoic acid) 4 g daily or Lovaza (EPA/DHA) 4 g daily; alternative DHA/EPA 4 g daily. [166] Vascepa and Lovaza tablets **must be swallowed** and cannot be crushed, dissolved, or chewed.

- *Optional:* **JAK inhibitors** ruxolitinib or baricitinib. JAK inhibitors target JAK1, JAK2, JAK3, and whose inhibition downregulates the JAK/STAT signaling pathway decreasing cytokine concentrations. [167] These drugs have been shown to decrease the use of mechanical ventilation and the risk of death. [168;169] In these studies, low doses of corticosteroids were used. The role of JAK inhibitors with appropriate corticosteroid dosing is unclear. JAK inhibitors should be used with caution in patients with severe renal impairment as well as those with lymphopenia (< 500) and neutropenia (< 1000). The safety of these drugs is uncertain, as they are nephrotoxic and myelosuppressive.

- *Not recommended:* **Remdesivir.** The SOLIDARITY trial demonstrated no mortality benefit of this agent in the entire treatment cohort or any subgroup. [170] The VA study showed no mortality benefit with remdesivir and a longer length of hospital stay. [171] Most recently, the DisCoVeRy trial reported no outcome benefit from remdesivir. [172] A meta-analysis of the six published RCTS demonstrate no mortality reduction with remdesivir; interestingly enough, the independent studies demonstrate a trend to harm while the two studies conducted by Gilead demonstrate a mortality benefit. (See Figure 6).

- Not recommended: **Colchicine**. Recruitment to the colchicine arm of the RECOVERY trial has been closed as no mortality benefit was noted (Mortality 20% colchicine, 19% standard of care). In addition, potentially serious drug-drug interactions exist with the use of colchicine and CYP 3A4 and p-glycoprotein inhibitors (ivermectin, macrolide antibiotics, cyclosporin, etc.) as well as with the use of statins. [173]

NOTE: Transfer patients to ICU as early as possible if respiratory symptoms worsen, oxygen requirements increase, or arterial desaturation emerges.

## Table 3. A Single-Dose Regimen of Calcifediol to Rapidly Raise Serum 25(OH)D above 50 ng/mL

Using a regimen of calcifediol * to rapidly raise serum 25(OH)D concentration above 50 ng/mL (125 nmol/L) in medical emergencies (i.e., to raise serum levels within four hours). ** A single body weight based, oral dose is calculated: 0.014 mg/kg body weight.

Weight (lbs)	Weight (kg)	Calcifediol ~ (mg) [#]	If Calcifediol Is Not Available: Bolus/Loading Dose of Vitamin D_3 [##]
8–14	4–6	0.05	20,000
15–21	7–10	0.1	40,000
22–30	10–14	0.15	60,000
31–40	15–18	0.2	80,000
41–50	19–23	0.3	100,000
51–60	24–27	0.4	150,000
61–70	28–32	0.5	200,000
71–85	33–39	0.6	240,000
86–100	40–45	0.7	280,000
101–150	46–68	0.8	320,000
151–200	69–90	1.0	400,000
201–300	91–136	1.5	600,000
>300	>137	2.0	800,000

Source: Nutrients'—Special Issue: "Vitamin D—Calcifediol and COVID" [174]

* Calcifediol [partially activated vitamin D3, 25(OH)D]. ** Use the earliest possible in person with COVID-19, sepsis, Kawasaki disease, multisystem inflammatory syndrome, acute respiratory distress syndrome, burns, and vitamin D deficiency in early pregnancy and other clinical emergencies. # Measurement (or the concentration) of serum 25(OH)D is unnecessary. ## If calcifediol is unavailable, the equivalent dose of vitamin D is administered, as illustrated in Table 2, preferably in divided doses over three to five days. Irrespective of the regimen used, daily or weekly follow-up maintenance vitamin D dose is necessary as described in the text.

Figure 5. Ivermectin for COVID-19: Real-time meta-analysis of 88 studies

Source: c19ivermectin.com

Figure 6. Meta-Analysis of the Remdesivir RCTs Grouped by Independent Studies (I) and Those Done by Gilead™ (P)

Group by Pharma/IND	Study name	Odds ratio	Lower limit	Upper limit	Z-Value	p-Value
I	Wang	1.116	0.501	2.488	0.269	0.788
I	SOLIDARITY	0.978	0.826	1.159	-0.254	0.800
I	VA Coperative	1.175	0.910	1.516	1.234	0.217
I	DisCoVery	0.866	0.475	1.581	-0.467	0.640
I		1.027	0.897	1.176	0.391	0.696
P	Beigel	0.724	0.507	1.035	-1.773	0.076
P	Spinner	0.249	0.045	1.370	-1.599	0.110
P		0.692	0.488	0.982	-2.062	0.039
Overall		0.976	0.860	1.107	-0.380	0.704

Meta Analysis

Treatment for Patients Admitted to ICU

First line treatments

- ***Methylprednisolone*** 80 mg loading dose followed by 40 mg every 12 hours for at least 7 days and until transferred out of ICU. In patients with an increasing C-reactive protein (CRP) or worsening clinical status increase the dose to 80 mg every 6 hours, then titrate down as appropriate. [37;91;104-114] Pulse methylprednisolone 500-1000 mg/day for 3 days (followed by taper) may be required. [112] We suggest that all patients admitted to the ICU have a chest CT scan on admission to allow risk stratification based on the extent of the disease; those with extensive disease should be initiated on high dose corticosteroids (see section below on severe COVID). As depicted in Table 4, methylprednisolone is the corticosteroid of choice. Observational and randomized studies have clearly demonstrated the superiority of methylprednisolone over low dose dexamethasone. [175;176] These clinical findings are supported by a genomic study. [94] Methylprednisolone should be weaned slowly over two weeks once oxygen is discontinued to prevent relapse/recurrence (20 mg twice daily of oxygen, then 20 mg/day for 5 days, then 10 mg/day for 5 days). While 1) methylprednisolone is the corticosteroid of choice (see below) in those regions/countries where it is not available the following (in order of preference) may be substituted for methylprednisolone (dose adjusted according to methylprednisolone dosages), 2) prednisolone, 3) prednisone, 4) hydrocortisone, and 5) LASTLY dexamethasone.

- ***Ascorbic acid (Vitamin C)*** 50 mg/kg (or 3000 mg) IV every 6 hours for at least 7 days and/or until transferred out of ICU. [80;81;85;177-187]. *High-dose Vitamin C* should be considered in severely ill patients, those with progressive respiratory failure and as salvage therapy: 25 g Vitamin C in 200-500 cc saline over 4-6 hours every 12 hours for 3-5 days, then 3 g IV every 6 hours for total of 7-10 days of treatment. [188] High-dose Vitamin C appears safe in patients with acute renal failure and end-stage renal disease. In patients with chronic renal failure, a dose of 12.5 g every 12 hours may be suitable. [189] In the study by Lankadeva et al, high-dose Vitamin C increased renal cortical blood flow and renal cortical pO2; oxalate crystals were not detected. [188] Note caution with POC glucose testing. Oral absorption is limited by saturable transport proteins, and it is difficult to achieve adequate levels with PO administration. However, should IV Vitamin C not be available, it would be acceptable to administer PO Vitamin C at a dose of 1 g every 4–6 hours*.

- ***Anticoagulation***: The ATTACC, ACTIV-4a & REMAP-CAP trials demonstrated a marginally increased mortality in ICU patients treated with full anti-coagulation (35.3% vs. 32.6%). [115] Critically ill COVID-19 patients frequently have impaired renal function and it is likely that in the absence of Xa monitoring patients were over-anticoagulated. However, full anti-coagulation should be continued on floor patients transitioned to the ICU who have normal renal function. In all other patients, we would suggest intermediate dose enoxaparin i.e 60 mg/day (enhanced thromboprophylaxis) or 0.5 mg/kg every 12 hours. [190] Full anticoagulation (enoxaparin or heparin) may be required in patients with increasing D-dimer or with thrombotic complications. Due to augmented renal clearance

some patients may have reduced anti-Xa activity despite standard dosages of LMWH. [236] We therefore recommend monitoring anti-Xa activity aiming for an anti-Xa activity of 0.5 – 0.9 IU/ml. Heparin is suggested with CrCl < 15 ml/min. It should also be appreciated that Vitamin C is a prerequisite for the synthesis of collagen and Vitamin C deficiency is classically associated with vascular bleeding. [85;179] This is relevant to COVID-19, as Vitamin C levels are undetectable in severely ill COVID-19 patients and this may partly explain the increased risks of anticoagulation in ICU patients (not treated with Vitamin C). [191-193] The use of the novel oral anticoagulants (NOAC/DOAC) is not recommended. [194]

Note: A falling SaO2 and the requirement for supplemental oxygen should be a trigger to start anti-inflammatory treatment.

Note: Early termination of ascorbic acid and corticosteroids will likely result in a rebound effect with clinical deterioration.

Additional Treatment Components

- *Highly recommended*: **Ivermectin** 0.6 mg/kg day orally for 5 days or until recovered [7-20;22-29;195]. Note that ivermectin has potent antiviral and anti-inflammatory effects. As noted above, clinical outcomes are superior with multiday as opposed to single day dosing.

- **Nitazoxanide** (NTZ) 600 mg twice daily for 7 days. [127] NTZ should be considered as an alternative to ivermectin, or as part of a multi-drug combination that includes ivermectin. It should be noted that while NTZ is relatively cheap in most of the world, it is very expensive in the USA.

- **Melatonin** 10 mg at night. [117-119]

- **Thiamine** 200 mg IV every 12 hours for 3-5 days, then 200 mg daily [196-201] Thiamine may play a role in dampening the cytokine storm. [197;202]

- **Aspirin/Acetylsalicylic acid** (ASA) 325 mg daily. COVID infection results in profound platelet activation contributing to the severe pro-thrombotic state and increasing the inflammatory response. [136-139] As the risk of significant bleeding is increased in patients receiving both ASA and heparin, ASA should not be used in patients at high risk of bleeding. In addition (as noted below) patients should receive famotidine concurrently.

- The anti-serotonin agent, **cyproheptadine**. Platelet activation results in the release of serotonin, which may contribute to the immune and vascular dysfunction associated with COVID-19. [215-219] Therefore, the serotonin receptor blocker cyproheptadine 4–8 mg by mouth every 6 hours should be considered.

- **Anti-androgen therapy** (both men and women). Spironolactone 100 mg twice daily for 10 days. Second line: Dutasteride 2 mg day 1, followed by 1 mg for 10 days. Finasteride 10 mg is an alternative (dutasteride cannot be crushed). [203;204] **AVOID IN PREGNANCY**. [145;146] Bicalutamide 150 mg daily is also an option.

- **Fluvoxamine** 50 mg twice daily. Fluoxetine 20-40 mg daily is an alternative. NOTE: Some individuals who are prescribed fluvoxamine experience acute anxiety, which needs to be carefully monitored for and treated by the prescribing clinician to prevent rare escalation to suicidal or violent behavior.

Second Line Treatments

- **B complex vitamins.**

- **Calcifediol** [25-hydroxylated vitamin D; 25(OH)D]. Dosing as suggested in Table 3.

- **Vascepa** (Ethyl eicosapentaenoic acid) 4 g daily or Lovaza (EPA/DHA) 4 g daily; alternative DHA/EPA 4 g daily. Vascepa and Lovaza tablets must be swallowed and cannot be crushed, dissolved, or chewed.

- **Magnesium** 2 g stat IV. Keep Mg between 2.0 and 2.2 mmol/l. [205] Prevent hypomagnesemia (which increases the cytokine storm and prolongs Qtc). [206-208]

Optional Treatments (and those of uncertain benefit)

- *Optional:* **Famotidine** 40 mg twice daily (20–40 mg/day in renal impairment). [148-154]

- *Optional:* **JAK inhibitors** ruxolitinib or baricitinib.

- *Optional:* **Atorvastatin** 40-80 mg/day (reduce dose to 40 mg if taken with ivermectin due to possible drug-drug interaction. Preliminary data suggests atorvastatin may improve outcome in patients with COVID-19. [238-242] Due to numerous drug-drug interactions, simvastatin should be avoided

- *Unclear benefit*. **Losartan** 50-100 mg/day (reduce to 25-50 mg with impaired renal function) or telmisartan 40-80 mg twice daily (reduce to 40 mg/day or twice daily with impaired renal function). [209-211]

- *Unclear benefit.* **Maraviroc** 300 mg twice daily for 10 days. Maraviroc is a CCR5 antagonist. [212] CCR5 is a chemokine that activates macrophages/monocytes and whose circulating levels are significantly increased in COVID-19. [213;214] Blocking the CCR5 receptor (CCR5R) repolarizes macrophages/monocytes and decreases the production of proinflammatory cytokines.

- *Not recommended:* **Remdesivir**. This drug has no benefit at this stage of the disease.

- *Not recommended.* **Convalescent serum** [215-220] nor **monoclonal antibodies**. [221] However, convalescent serum/monoclonal antibodies may have a role in patients with hematologic malignancies. [222] The role of bebtetovimab requires further evaluation. [223]

- *Not recommended.* **Colchicine** (see above).

- *Not recommended.* **Tocilizumab**. Five RCTs have now failed to demonstrate a clinical benefit from tocilizumab. [224-228] Considering the effect of IL-6 inhibitors on the profile of dysregulated inflammatory mediators this finding is not surprising. [229] Tocilizumab may have benefit in patients receiving an inadequate dose of corticosteroids. [230] In patients who receive an adequate therapeutic dose of corticosteroid the role of this drug appears limited.

- **Broad-spectrum antibiotics** added if complicating bacterial pneumonia is suspected based on procalcitonin levels and respiratory culture (no bronchoscopy). Due to the paradox of hyper-inflammation and immune suppression (a major decrease of HLA-DR on CD14 monocytes, T cell dysfunction and decreased CD4 and CD8 counts) secondary bacterial and fungal infections (Candida and Aspergillus species) and viral reactivation is not uncommon. [231-233] Patients with non-resolving fever, increasing WBC count and progressive pulmonary infiltrates should be screened for COVID-19-associated pulmonary aspergillosis (CAPA). [234] Recommended first-line therapy for CAPA is either voriconazole or isavuconazole (beware drug-drug interactions). While low CD4 counts are typical of severe COVID-19 infection, PJP infections have not been reported; therefore, PJP prophylaxis is not required.

- Maintain *EUVOLEMIA* (this is not non-cardiogenic pulmonary edema). Due to the prolonged "symptomatic phase" with flu-like symptoms (6–8 days) patients may be volume depleted. Cautious rehydration with 500 ml boluses of Lactate Ringers may be warranted, ideally guided by non-invasive hemodynamic monitoring. Diuretics should be avoided unless the patient has obvious intravascular volume overload. Avoid hypovolemia.

- Early **norepinephrine** for hypotension. It should however be appreciated that despite the cytokine storm, vasodilatory shock is distinctly uncommon in uncomplicated COVID-19 (when not complicated by bacterial sepsis). This appears to be due to the fact that TNF-α which is "necessary" for vasodilatory shock is only minimally elevated.

- Escalation of **respiratory support** (steps); *Try to avoid intubation if at all possible.* Intubation is indicated in patients who have failed non-invasive ventilation and in those patients with excessive work of breathing. A subgroup of patients with COVID-19 deteriorates very rapidly. Intubation and mechanical ventilation may be required in these patients.
    a. Accept "permissive hypoxemia" (keep O2 Saturation > 84%); follow venous lactate and Central Venous O$_2$ saturations (ScvO$_2$) in patents with low arterial O$_2$ saturations
    b. N/C 1–6 L/min
    c. High Flow Nasal canula (HFNC) up to 60–80 L/min [235]
    d. Trial of inhaled Flolan (epoprostenol)
    e. Attempt proning (cooperative repositioning-proning) [236-239]
    f. Intubation … by Expert intubator; Rapid sequence. No Bagging; Full PPE. Crash/emergency intubations should be avoided.
    g. Volume protective ventilation; Lowest driving pressure and lowest PEEP as possible. Keep driving pressures < 15 cm H$_2$O.
    h. Moderate sedation to prevent self-extubation
    i. Trial of inhaled Flolan (epoprostenol)
    j. Prone positioning

There is widespread concern that using HFNC could increase the risk of viral transmission. There is, however, no evidence to support this fear. [240;241] HFNC is a better option for the patient and the healthcare system than intubation and mechanical ventilation. HFNC is preferred over conventional oxygen therapy. [235] Intermittent CPAP/BiPAP may be used in select patients, notably those with COPD exacerbation or heart failure.

Figure 7. "Typical" Progression of Chest CT Findings

Source: FLCCC

Table 4: Comparison of Methylprednisolone, Dexamethasone and Hydrocortisone - Number Needed to Treat

PUBLISHED RCT's/OCT's OF CORTICOSTEROID THERAPY IN COVID-19		ABSOLUTE DIFFERENCE IN MORTALITY	NUMBER NEEDED TO TREAT TO SAVE ONE LIFE
METHYLPREDNISONE – HOSPITAL PATIENTS (Edalatifard et al, Italy) 250mg methylprednisone daily x 3 days		5.9% vs. 42.9%	2.7
METHYLPREDNISONE – ICU PATIENTS (Confalonieri et al, Italy) 80mg methylprednisone daily x 8 days		7.2% vs. 23.3%	6.2
METHYLPREDNISONE- ARDS PATIENTS (OCT - Wu C et al- China) 1-2 mg/kg/day for 3-5 days		46.0% vs. 61.8%	6.3
METHLPREDNISONE – HOSPITAL PATIENTS, (OCT - Fadel et al, USA) 0.5-1.0mg/kg/day x 3 days		13.6% vs. 26.3%	7.8
METHYLPREDNISONE - Pts on oxygen – (Fernandez-Cruz at al, Spain) 1mg/kg/day		13.9% vs. 23.9%	10.0
METHYLPREDNISONE VS. DEXAMETHASONE (Ranjbar et al, Iran) 2mg/kg/day MP vs. 6mg/day Dexamethasone		18.6% vs 37.5%	5.3
METHYLPREDNISONE VS. DEXAMETHASONE (OCT - Ko et al, USC) >= 1mg/kg/day MP for min. 3 days vs. 6mg/day Dex for min. 7 days	OVERALL	16.4% vs. 26.5%	10
	PTS ON MV	31% vs. 54%	4.3
HYDROCORTISONE -CAPE-COVID – ICU Patients (Dequin et al France) 200mg/day with taper over 14 days – stopped early		14.7% vs 27.4%	7.9
HYDROCORTISONE –REMAP-CAP – ICU Patients (Angus et al) 200 - 400 mg/day x 7 days – stopped early		28% vs 33% (NS)	20.0
DEXAMETHASONE – CODEX – ICU Patients (Tomazini et al) 20 mg x 5 days, 10 mg x 5 days		56.3% vs 61.5%	19.2
DEXAMATHASONE – RECOVERY (Hornsby et al) 6mg/day x 10 days	PTS ON OXYGEN	23.3% vs. 26.2%	28.6
	PTS ON MV	29.3% vs. 41.4%	8.4

Source: FLCCC

Patients with Severe, Life Threatening COVID-19 Organizing Pneumonia

The first task of the clinician is to determine the reversibility of the pulmonary disease. This is a critical assessment. Aggressive anti-inflammatory treatment is futile in patients with advanced fibrotic lung disease. The horse has already bolted and allowing the patient a "peaceful death" is the most compassionate and humane approach.

The reversibility of the pulmonary disease is dependent on a number of factors superseded by a good deal of clinical judgement; these include:

a) The length of time that has elapsed since the onset of symptoms. Early aggressive treatment is critical to prevent disease progression. With each day the disease becomes more difficult to reverse. The 'traditional' approach of supportive care alone is simply unacceptable.

b) The level of inflammatory biomarkers, particularly the CRP. In general the CRP tracks the level of pulmonary inflammation. [242] A high CRP is indicative of a hyper-inflammatory state and potentially reversible pulmonary inflammation.

c) It is likely that advanced age is a moderating factor making the pulmonary disease less reversible.

d) A chest CT is extremely helpful in determining the reversibility of disease. BEWARE: this is not ARDS but organizing pneumonia. [63] The extent of the pulmonary involvement may be determined qualitatively or preferably quantitatively (see Figure 7). [242-249] The Ichikado CT Score is a useful quantitative score to evaluate the extent of lung involvement with COVID-19. [250;251] The changes in the CT follow a stereotypic progressive pattern:

   I.   Peripheral, patchy, predominantly basal ground glass opacification (GGO). GGO is defined an increase in density of lung with visualization of bronchial and vascular structures through it

   II.   Progressive widespread bilateral GGO

       I.   Crazy-paving (CGO with interlobular and intralobular septal thickening)

       II.   Air space consolidation (air bronchograms)

       III.   Dense airspace consolidation

       IV.   Coalescent consolidation

       V.   Segmental/subsegmental pulmonary vessel dilatation

       VI.   Bronchial wall thickening

       VII.   Linear opacities

       VIII.   Traction bronchiectasis

       IX.   Cavitation

       X.   Fibrotic changes with bullae and reticulation

GGO pattern is significantly more prevalent in early-phase disease compared with late-phase disease while crazy-paving and consolidation patterns are significantly more common in late-phase. [242] Therefore widespread GGO suggests reversibility while widespread consolidation with other features of more advanced disease suggest irreversible lung disease. However, when in doubt (borderline cases) a time-limited therapeutic trial of the aggressive "Full Monty" approach may be warranted.

The "FULL MONTY" for Severe COVID Pulmonary Disease

I. Methylprednisolone 250-500 mg every 12 hours for at least 3 days, then titrate guided by clinical status and CRP

II. Ivermectin 1 mg/kg for 5 days

III. Melatonin 10 mg by mouth at night

IV. Enoxaparin 60 mg daily; critically ill patients usually have some degree of renal impairment and will require a renally adjusted lower dose. Patients with very high D-dimer and or thrombotic complications may require full anticoagulant doses of Lovenox. It may be prudent to monitor Xa levels aiming for 0.4-0.8 IU/ml (a somewhat lower anti-Xa).

V. Vitamin C 3 g every 6 hours to 25 g every 12 hours

VI. Cyproheptadine 4–8 mg by mouth every 6 hours

VII. Fluvoxamine 50-100 mg twice daily or fluoxetine 20-40 mg daily

VIII. Spironolactone 100 mg twice daily

IX. Thiamine 200 mg every 12 hours

X. NAC 1200 mg by mouth twice daily [142]

XI. Finasteride 10 mg daily or dutasteride 2 mg day 1 then 1 mg daily or bicalutamide 150 mg daily

XII. Omega-3 fatty acids 4 g/day

XIII. Famotidine 40 mg twice daily

XIV. Calcifediol (0.014 mg/kg) use as a single dose (see Table 3)

XV. Consider plasma exchange on admission to the ICU

All these drugs have been shown to be safe and independently to improve the outcome of patients with COVID-19. Ultimately it is irrelevant as to the contribution of each element as long as the patient improves and survives his/her ICU stay. In the midst of a pandemic caused by a virus resulting in devastating lung disease, there is no place for "ivory tower medicine."

Salvage Treatments

- High dose bolus corticosteroids: 500–1000 mg/day methylprednisolone for 3 days then taper. [110;112]

- Plasma exchange [252-258]. Should be considered in patients with progressive oxygenation failure despite corticosteroid therapy as well as in patients with severe MAS. Patients may require up to 5 exchanges. FFP is required for the exchange; giving back "good humors" appears to be more important than taking out "bad humors".

- Calcifediol (0.014 mg/kg) use as a single dose (see Table 3).

- Mega-dose Vitamin C should be considered in severely ill patients and as salvage therapy: 25 g Vitamin C in 200-500 cc saline over 4-6 hours, 12 hourly for 3-5 days, then 3g IV 6 hourly for total of 7-10 days of treatment. [188;189]

- In patients with a large dead-space ventilation (i.e., high $PaCO_2$ despite adequate minute ventilation) consider "Half-dose rTPA" to improve pulmonary microvascular blood flow; 25 mg of tPA over 2 hours followed by a 25 mg tPA infusion administered over the subsequent 22 hours, with a dose not to exceed 0.9 mg/kg followed by full anticoagulation. [259;260]

- Combination inhaled nitric oxide (or epoprostenol) and intravenous almitrine (10–16 ug/kg/min). The combination of inhaled nitric oxide, a selective pulmonary vasodilator, and almitrine, a specific pulmonary vasoconstrictor, may improve the severe V/Q mismatch in patients with severe COVID-19 "pneumonia". [261-264]

- ECMO [265-267]. Unlike "typical ARDS", COVID-19 patients may not progress into a resolution phase. Rather, patients with COVID-19 with unresolved inflammation may progress to a severe fibro-proliferative phase and ventilator dependency. ECMO in these patients would likely serve little purpose. ECMO however may improve survival in patients with severe single organ failure (lung) if initiated within 7 days of intubation. [268]

- Lung transplantation. [269]

Salvage Treatments of Unproven/No Benefit

- Convalescent serum/monoclonal antibodies: Four RCTs failed to demonstrate a clinical benefit with the use of convalescent serum. [215-217;219;220] Eli Lilly suspended the ACTIV-33 clinical trial as their monoclonal antibody failed to demonstrate a clinical benefit in hospitalized patients.[270] It is noteworthy that the only RCT demonstrating efficacy of convalescent plasma for an infectious disease was conducted more than 40 years ago, for treating Argentine hemorrhagic fever. [211] Furthermore, giving antibodies directed against SARS-CoV-2 appears pointless when the virus is already dead (i.e., pulmonary phase). In addition, IgG is a large protein that penetrates tissues poorly, and is unlikely to achieve submucosal concentrations required for mucosal immunity. [271] Lastly, COVID-19 pulmonary disease is immune mediated, and it would therefore appear paradoxical to enhance the antibody response with convalescent serum. [272]

- In patients with progressive fibrosis, the combination of anti-fibrotic therapy with corticosteroids should be considered. [273-276] It should however be recognized that unlike all the medications in the MATH+ protocol, pirfenidone and nintedanib have complex side-effects and drug interactions and should be prescribed by pulmonary physicians who have experience with these drugs.

- CVVH/D with cytokine absorbing/filtering filters [277;278] This treatment strategy appears to have an extremely limited role.

Monitoring

- On admission: Procalcitonin (PCT), CRP, BNP, Troponins, Ferritin, Neutrophil-Lymphocyte ratio, D-dimer and Mg. CRP and D-dimer are important prognostic markers. [279] A PCT is essential to rule out coexisting bacterial pneumonia. [280]

- As indicated above (corticosteroid section), a chest CT scan on admission to the ICU is very useful for risk stratification and for the initial corticosteroid dosing strategy. The Ichikado Score is a quantitative method to assess the extent of lung involvement on the CT scan. [250;281] Follow-up CXR, CT scan (if indicated) and chest ultrasound as clinically indicated.

- Daily: *CRP, Ferritin, D-Dimer and PCT*. CRP and Ferritin track disease severity closely (although ferritin tends to lag behind CRP). Early high CRP levels are closely associated with the degree of pulmonary involvement and the CT score. [282]

- In patients receiving IV vitamin C, the Accu-Chek™ POC glucose monitor will result in spuriously high blood glucose values. Therefore, a laboratory glucose is recommended to confirm the blood glucose levels. [283;284]

- ECHO as clinically indicated; Patients may develop a severe "septic" cardiomyopathy and/or COVID-19 myocarditis. [285;286]

Post ICU Management
- Enoxaparin 40–60 mg s/c daily

- Methylprednisolone 40 mg day, then wean slowly, follow CRP and oxygen requirements – wean off over two weeks once oxygen is discontinued to prevent relapse/recurrence

- Vitamin C 500 mg PO BID

- Melatonin 3–6 mg at night

- Vascepa, Lovaza or DHA/EPA 4g day

- Atorvastatin 40mg daily

Post Hospital Discharge Management
Patients have an increased risk of thromboembolic events post-discharge. [287;288] Extended thromboprophylaxis (with a DOAC) should be considered in high-risk patients. Risk factors include: [289]

i. Increased D dimer (> 3 times ULN)

ii. Increased CRP (> 2 times ULN) [290]

iii. Age > 60

iv. Prolonged immobilization

   a. Patients with unresolved pulmonary infiltrates and/or those who remain dyspneic and/or oxygen dependent should be discharged on a tapering course of corticosteroids (prednisone).

   b. Patients should continue to receive Vitamin C, melatonin, Omega-3 fatty acids and a statin. These agents may reduce this risk of developing long COVID.

   c. *Nigella sativa* and Kefir.

   d. Patients should be followed/monitored for developing long COVID.

References

1. Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012; 87:982-990.
2. Peterson DJ. Prescription of ivermectin or hydroxychloroquine as off-label medicines for the prevention and treatment of Covid-19. https://ago nebraska gov/sites/ago nebraska gov/files/docs/opinions/21-017_0 pdf [2021 [cited 2022 Jan. 14];
3. Kennedy RF. The Real Anthony Fauci. Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. New York, NY: Skyhorse Publishing; 2021.
4. Fatima S, Zaidi SS, Alsharidah AS, Alijaser FS, Banu N. Possible prophylactic approach for SARS-CoV-2 infection by combination of melatonin, Vitamin C and Zinc in animals. Fronteirs in Veterinary Science 2020; 7:585789.
5. Arslan B, Ergun NU, Topuz S, Semerci SY, Suner N. Synergistic effect of quercetin and vitamin C against COVID-19: Is a possible guard for front liners? ssrn 2020.
6. Ahmed AK, Albalawi YS, Shora HA, Abelseed HK, Al-Kattan AN. Effects of quadruple therapy: Zinc, Quercetin, Bromelain and Vitamin C on clinical outcomes of patients infected with COVID-19. Rea Int Jou of End and Dia 2020; 1:1005.
7. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020.
8. Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo 2020; 34:3023-3026.
9. Maurya DK. A combination of Ivermectin and Doxycycline possibly blocks the viral entry and modulate the innate immune response in COVID-19 patients. ChemRxiv 2020.
10. Yang SN, Atkinson SC, Wang C, Lee A. The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. Antiviral Res 2020; 177:104760.
11. Dayer MR. Coronavirus (2019-nCoV) deactivation via spike glycoprotein shielding by old drugs, bioinformatic study. Preprints 2020.
12. Swargiary A. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from silico studies. Research Square 2020.
13. Zhang X, Song Y, Ci X, An N, Ju Y. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res 2008; 57:524-529.
14. Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen activated protein kinase pathway. Fundamental & Clinical Pharmacology 2009; 23:449-455.
15. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. ICON (Ivermectin in COvid Ninteen) study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19. Chest 2020.
16. Gorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM. Effectiveness of Ivermectin as add-on therapy in COVID-19 management (Pilot Trial). medRxiv 2020.
17. Khan MS, Khan MS, Debnath Cr, Nath PN, Mahtab MA. Ivermectin treatment may improve the prognosis of patients with COVID-19. Archivos de Bronconeumologia 2020.

18. Hashim HA, Maulood MF, rasheed AM, Fatak DF, Kabah KK. Controlled randomized clinical triaal on using Ivermectin with Doxycycline for treating COVID-19 patients in Bagdad, Iraq. medRxiv 2020.

19. Murshed MR, Bhiuyan E, Saber S, Alam RF, Robin RF. A case series of 100 COVID-19 positive patients treated with combination of Ivermectin and Doxycycline. Bangladesh Coll Phys Surg 2020; 38:10-15.

20. Chamie J. Real-World evidence: The case of Peru, casuality between Ivermectin and COVID-19 infection fatality rate. ResearchGate 2020.

21. Patel AN, Desai SS, Grainger DW, Mehra MR. Usefulness of ivermectin in COVID-19 illness. medRxiv 2020.

22. Jans DA, Wagstaff KM. Ivermectin as a broad-spectrum host directed anti-viral: The real deal. Cells 2020; 9:2100.

23. DiNicolantonio JJ, Barroso-Arranda J, McCarty M. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart 2020; 7:e001350.

24. Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob 2020; 19:23.

25. Peralta EG, Fimia-Duarte R, Cardenas JW, Dominguez DV, Segura RB. Ivermectin, a drug to be considered for the prevention and treatment of SARS-CoV-2. Brief literature review. EC Veterinary Science 2020; 5:25-29.

26. Al-Jassim KB, Jawad AA, Al-Masoudi EA, Majeed SK. Histopathological and biochemical effects of ivermectin on kidney functions, lung and the ameliorative effects of vitamin C in rabbits. Bas J Vet Res 2016; 14:110-124.

27. Mudatsir M, Yufika A, Nainu F, Frediansyah A, Megawati D. Antiviral activity of ivermectin against SARS-CoV-2: an old-fashioned dog with a new trick- Literature review. Sci Pharm 2020; 88:36.

28. Carvallo H, Hirsch R, Farinella ME. Safety and efficacy of the combined use of Ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. medRxiv 2020.

29. Kircik LH, Del Rosso JQ, Layton AM, schauber J. Over 25 years of clinical experience with Ivermectin: An overview of safety for an increasing number of indications. J Drugs Dermatol 2016; 15:325-332.

30. Kurcicka L, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polmerase chain reacion-based SARS-CoV-2 tests by time since exposure. Ann Intern Med 2020; 173:262-267.

31. Cheng HY, Jian SW, Liu DP, Huang WT, Lin HH. Contact tracing assessment of COVI-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med 2020; 180:1156-1163.

32. Zhao J, Yang Y, Huang H, Li D, Gu D. Relationship between ABO blood group and the COVID-19 susceptibility. medRxiv 2020.

33. Banerjee A, Pasea L, Harris S, Gonzalez-Izquierdo A. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Lancet 2020; 395:1715-1725.

34. Goren A, Vamo-Galvan S, Wambier CG, McCoy J. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain- A potential clue to the role of androgens in COVID-19 severity. J Cosmetic Dermatol 2020.

35. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China. Lancet 2020; 395:497-506.

36. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020.
37. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan,China. JAMA Intern Med 2020.
38. von der Thusen J, van der Eerden M. Histopathology and genetic susceptibility in COVID-19 pneumonia. Eur J Clin Invest 2020.
39. Sweeney TE, Liesenfeld O, Wacker J, He YD, rawling D, Remmel M. Validation of inflammopathic, adaptive, and coagulopathic sepsis endotypes in Coronavirus disease 2019. Crit Care Med 2020.
40. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H. Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization. Ann Intern Med 2020.
41. Pujadas E, Chaudhry F, McBride R, Richter F, Zhao S. SARS-CoV-2 viral load predictes COVID-19 mortality. Lancet Resp Med 2020.
42. Akbar AN, Gilroy DW. Aging immunity may exacerbate COVID-19. Science 2020; 369.
43. Zhang Q, Bastard P, Liu Z, Le Pen J, Chen J, Korol C. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020.
44. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infectious Diseases of Poverty 2020; 9:45.
45. Zhou Y, Fu B, Zheng X, Wang D, Zhao C. Pathogenic T cellls and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev 2020; 7:998-1002.
46. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020; 181:1036-1045.
47. Giamarellos-Bouboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host & Microbe 2020.
48. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induces pneumonia and macrophage activation syndrome-like disease. Autoimmunity Reviews 2020; 19:102537.
49. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factor for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020.
50. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Febratinib. J Microbiol Immunol Infect 2020.
51. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. medRxiv 2020.
52. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033-1034.
53. Qin C, Zhou L, Hu Z, Zhang S. Dysregulation of the immune response in patiens with COID-19 in Wuhan, China. Lancet Infect Dis 2020.
54. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonsit Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020.
55. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the "Cytokine Storm" in COVID-19. J Infection 2020.

56. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020.

57. Tay MZ, Poh CM, Renia L, MacAry PA. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews 2020; 20:363-374.

58. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med 2020; 46:1105-1108.

59. Bryce C, Grimes Z, Pujadas E, Ahuja S, Beasley MB, Albrecht R et al. Pathopysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. medRxiv 2020.

60. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nature Reviews 2020.

61. Varga Z, Flammer AJ, Steiger P, Habrecker M, Andermatt R, Zinkernagel AS. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020.

62. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T. Pulmonary vascular endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N Engl J Med 2020; 383:120-128.

63. Kory P, Kanne JP. SARS-CoV-2 organizing pneumonia:"Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?'. BMJ Open Resp Res 2020; 7:e000724.

64. Torrealba JR, Fisher S, Kanne JP, Butt YM, Glazer C, Kershaw C. Pathology-radiology correlation of common and uncommon computed tomographic patterns of organizing pneumonia. Human Pathology 2018; 71:30-40.

65. Jeronimo CM, Farias ME, Almeida FF, Sampaio VS, Alexandre MA, Melo GC. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): A ramdomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis 2020.

66. Kanne JP, Little BP, Chung JH, Elicker BM. Essentials for radiologists on COVID-19: an Update-Radiology Scientific Expert Panel. Radiology 2020.

67. Copin MC, Parmentier E, Duburcq T, Poissy J, Mathieu D. Time to consider histologic pattern of lung injury to treat critically ill patietns with COVID-19 infection [letter]. Intensive Care Med 2020.

68. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L. COVID-19 pneumonia: different respiratory treatment for different phenotypes? Intensive Care Med 2020; 46:1099-1102.

69. Chiumello D, Cressoni M, Gattinoni L. Covid-19 does not lead to a "typical" Acute Respiratory Distress syndrome. Lancet 2020.

70. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care 2020; 24:154.

71. Gattinoni L, Pesenti A. The concept of "baby lung". Intensive Care Med 2005; 31(6):776-784.

72. Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. Am J Respir Crit Care Med 2020.

73. Schurink B, Roos E, Radonic T, Barbe E, Bouman CS. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe 2020.

74. Buijsers B, Yanginlar C, Maciej-Hulme ML, de Mast Q. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine 2020.

75. Kim SY, Jin W, Sood A, Montgomery DW, Grant OC, Fuster MM. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res 2020; 181:104873.

76. Clausen TM, Sandoval DR, Spliid CB, PiHl J, Painter CD, Thacker BE et al. SARS-CoV-2 infection depends on cellular heparan sulphate and ACE2. bioRxiv 2020.

77. Kwon PS, Oh H, Kwon SJ, Jin W, Zhang F, Fraser K et al. Sulphated polysaccharides effectively inhibit SARS-CoV-2 in vitro. Cell Discovery 2020; 6:50.

78. Huang X, Han S, Liu x, Wang T, Xu H. Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis. Exp Thera Med 2020; 19:913-922.

79. Buijsers B, Yanginlar C, de Nooijer A, Grondman I, Jonkman I, Rother N. Increased plasma heparanase activity in COVID-19 patients. medRxiv 2020.

80. Barabutis N, Khangoora V, Marik PE, Catravas JD. Hydrocortisone and Ascorbic Acid synergistically protect and repair lipopolysaccharide-induced pulmonary endothelial barrier dysfunction. Chest 2017; 152:954-962.

81. de Melo AF, Homem-de-Mello M. High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection. Crit Care 2020; 24:500.

82. May JM, Qu ZC. Ascorbic acid prevents oxidant-induced increases in endothelial permeability. Biofactors 2011; 37:46-50.

83. Utoguchi N, Ikeda K, Saeki K, Oka N, Mizuguchi H, Kubo K et al. Ascorbic acid stimulates barrier function of cultured endothelial cell monolayer. Journal of Cellular Physiology 1995; 163(2):393-399.

84. Han M, Pendem S, Teh SL, Sukumaran DK, Wu F, Wilson JX. Ascorbate protects endothelial barrier function during septic insult: Role of protein phosphatase type 2A. Free Radic Biol Med 2010; 48:128-135.

85. Marik PE. Hydrocortisone, Ascorbic Acid and Thiamine (HAT therapy) for the treatment of sepsis. Focus on ascorbic acid. Nutrients 2018; 10:1762.

86. Colunga Biancatelli RM, Berrill M, Marik PE. The antiviral properties of vitamin C. Expert Rev Anti Infect Ther 2020; 18:99-101.

87. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci 2004; 1024:138-146.

88. Shodell M, Siegal FP. Corticosteroids depress INF-alpha-producing plasmacytoid dentritic cells in human blood. J Allergy Clin Immunol 2001; 108:446-448.

89. Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Scientific Reports 2014; 4:7176.

90. Singanayagam A, Glanville N, Girkin JL, Ching YM, Marcellini A. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nature Communications 2018; 9:2229.

91. Liu J, Zheng X, Huang Y, Shan H, Huang J. Successful use of methylprednisolone for treating severe COVID-19. J Allergy Clin Immunol 2020.

92. Salton F, Confalonieri P, Santus P, Harari S, Scala R, Lanini S et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. medRxiv 2020.

93. Braude AC, Rebuck AS. Prednisone and methylprednisolone disposition in the lung. Lancet 1983;995-997.

94. Draghici S, Nguyen TM, Sonna LA, Ziraldo C, Vanciu R, Fadel R et al. COVID-19: disease pathways and gene expression chnages predict methylprednisolone can improve outcome in severe cases. Bioinformatics 2020.

95. Niaee MS, Gheibl N, Namdar P, Allami A, Javadi A. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. Research Square 2020.

96. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of Ivermectin and Doxycycline. Bangladesh Coll Phys Surg 2020; 38:10-15.

97. Chowdhury AT, Shahabz M, Karim MR, Islam J, Guo D, He D. A randomized trial of ivermectin-doxycycline and hydrochloroquine-azithromycin therapy on COVID-19 patients. Research Square 2020.

98. Kory P, Meduri GU, Iglesias J, Varon J, Berkowitz K, Wagshul F et al. Review of the emerging evidencce supporting the use of Ivermectin in the prophylaxis and treatment of COVID-19. Front Line Covid-19 Critical Care Alliance. osf io 2020.

99. Chamie-Quintero JJ, Hibberd JA, Scheim DE. Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=0.002 for effect by state, then 13-fold increase after ivermectin use restricted. medRxiv 2021.

100. Hazan S, Dave S, Gunaratne AW, Dolai S, Clancy RL, McCullough PA et al. Effectiveness of ivermectin-based multidrug therrapy in severe hypoxic ambulatory COVID-19 patients. medRxiv 2021.

101. Bryant A, Lawrie TA, Dowswell T, Fordham E, Mitchell S, Hill SR et al. Ivermectin for the prevention and treatment of COVID-19 infection: a systematic review and meta-analysis. Lancet 2021.

102. Hill A, Garratt A, Levi J, Falconer J, Ellis L, McCann K et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infectious Diseases 2021.

103. DiNicolantonio JJ, Barroso-Aranda J, McCarty MF. Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors. Open Heart 2021; 8:e001655.

104. Villar J, Confalonieri M, Pastores SM, Meduri GU. Rationale for prolonged corticosteroid tratment in the acute respiratory distress syndrome (ARDS) caused by COVID-19. Crit Care Expl 2020; 2:e0111.

105. Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudry Z, Bhargava P et al. Early course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 2020; 71:2114-2120.

106. Chroboczek T, Lacoste M, Wackenheim C, Challan-Belval T, Amar B, Boisson T. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis. medRxiv 2020.

107. Cruz AF, Ruiz-Antoran B, Gomez AM, Lopez AS. Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: A retrospective controlled cohort study. medRxiv 2020.

108. Meduri GU, Bridges L, Shih MC, Marik PE, Siemienluk RA, Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outomces: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med 2016; 42:829-840.

109. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. A meta-analysis. JAMA 2020.

110. Ruiz-Irastorza G, Pijoan JI, Bereciatua E, Dunder S, Dominguez J, Garcia-Escudero P. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. medRxiv 2020.
111. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC. Effect of dexamethasone on days alive and ventilaor-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. The CoDEX randomized clinical trial. JAMA 2020; 324:1307-1316.
112. Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S. Intravenous methylprednisolone pulse as a treatment for hospitalized severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J 2020.
113. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020.
114. Dequin PF, Heming N, Meziani F, Plantefeve G, Voiriot G. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19. A randomized Clinical trial. JAMA 2020.
115. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 2021; 389:790-802.
116. Gandolfi JV, Di Bernardo AP, Chanes DA, Martin DF, Joles VB, Amendola CP et al. The effects of melatonin supplementation on sleep quality and assessment of the serum melatonin in ICU patients: A randomized controlled trial. Crit Care Med 2020.
117. Castillo RR, Quizon GR, Juco MJ, Roman AD, de Leon DG, Punzalan FE et al. Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series. Melatonin Res 2021; 3:297-310.
118. Ramiall V, Zucker J, Tatonetti N. Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv 2021.
119. Farnoosh G, Akbaariqomi M, Badri T, Bagheri M, Izadi M. Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: A randomized, double-blind clinical trial. medRxiv 2021.
120. Hasan ZT, AlAtrakji MQ, Mehuaiden AK. The effect of melatonin on thrombosis, sepsis and mortality rate in COVID-19 patients. International Journal of Infectious Diseases 2022; 114:79-84.
121. Farnoosh G, Akbariqomi M, Badri T, Bagheri M, Izadi M, rezaie E. Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patietns with COVID-19: A randomized, double-blind clinical trial. Archives of Medical Research 2021.
122. Darban M, Malek F, Memarian M, Gohari A, Kiani A, Emadi A. Efficacy of high dose vitamin C, melatonin and zinc in Iranian patients with acute respiratory sydrome due to Coronavirus infection: A pilot randomized trial. Journal of Cellular & Molecular Anesthesia 2021; 6:164-167.
123. Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Likic R. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol 2021.
124. Reis G, Moreira-Silva EA, Silva DC, Thabane L, Guyatt GH, Mills EJ. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among

125. Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: A review of its mechanism of action and its role in COVID-19. Fronteirs in Pharmacology 2021; 12:652688.

126. Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Sirota M. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Network Open 2021; 4:e2133090.

127. Blum VF, Cimerman S, Huneter JR, Tierno P, Lacerda A, Soeiro A. Nitazoxanide superioroty to placebo to treat moderate COVID-19 - A pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine 2021; 37:100981.

128. Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 2008; 87:1738-1742.

129. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF. Effect of vitamin D3 supplementaion vs placebo on hospital length of stay in patients with severe COVID-19: A multicenter, double-blind, randomized controlled trial. JAMA 2020.

130. Castillo ME, Costa LM, Barrios JM, Diaz JF, Miranda JL, Bouillon R et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol 2020; 203:105751.

131. Loucera C, Pena-Chilet M, Esteban-Medina M, Villegas R, Lopez-Miranda J. Real world evidence of calcifediol use and mortality rate of COVID-19 hospitalized in a large cohort of 16,401 Adalusian patients. medRxiv 2021.

132. Nogues X, Overjero D, Pineda-Moncus M, Bouillon R. Calcifediol treatment and COVId-19-related outcomes. medRxiv 2021.

133. Loucera C, Pena-Chilet M, Esteban-Medina M, Villegas R, Tunez I. Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients. Scientific Reports 2021; 11:23380.

134. Henriquez MS, de Tejada Romero MJ. Cholecalciferol or calcifediol in the management of vitamin D deficiency. Nutrients 2020; 12:1617.

135. Elamir YM, Amir H, Lim S, Rana Y, Lopez CG, Omar A. A randomized pilot study using calcitriol in hospitalized patients. Bone 2022; 154:116175.

136. Hottz ED, Azevedo-Quintanilha Ig, Palhinha L, Teixeira L, Barreto EA. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood 2020; 136:1330-1341.

137. Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P. Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. Circulation Research 2020; 127:945-947.

138. Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. Journal of hematology & oncology 2020; 13:120.

139. Cloutier N, Allaeys I, Marcoux G, Machius KR, Mailhot B. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. PNAS 2018;E1550-E1559.

140. De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J 2020.

141. Shi Z, Puyo CA. N-Acetylcysteine to combat COVID-19: an evidence review. Therapeutics and Clinical Risk Management 2020; 16:1047-1055.

142. Assimakopoulos SF, Aretha D, Kominos D, Dimitropoulou D, Lagadinou M. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. Infectious Diseases 2021; 53(11):847-854.

143. Kumar P, Osahon O, Vides DB, Hanania N, Minard CG. Severe glutathione deficiency, oxidative stress and oxidant damage in adults hospitalized with COVID-19: implications for GlyNac (Glycine and N-acetylcysteine) supplementaion. Antioxidants 2022; 11(50).

144. Izquierdo JL, Soriano JB, Gonzalez Y, Lumbreras S. Use of N-Acetylcysteine at high doses as an oral treatment for patients with COVID-19. Science Progress 2022; 105.

145. McCoy J, Goren A, Cadegiani FA, Vano-Galvan S, Kovacevic M, Situm M et al. Proxalutamide reduces the rates of hospitalization for COVID-19 male outpatients: A randomized double-blinded placebo-controlled trial. Front Med 2021; 8:668698.

146. Cadegiani FA, McCoy J, Zimerman A, Mirza FN, Barros RN. Efficacy of proxalutamide in hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled, parallel-design clinical trial. medRxiv 2021.

147. Cadegiani FA, McCoy J, Wambier CG, Goren A. Early antiandrogen therapy with dutasteride reduces viral shedding, inflammatory responses, and time-to remission in males with COVID-19: A randomized, double-blind, placebo-controlled interventional trial (EAT-DUTA AndroCoV Trial- Biochemical). Cureus 2021.

148. Freedberg DE, Conigliaro J, Sobieszczyk ME, Markowitz DD. Famotidine use is associated with impoved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. medRxiv 2020.

149. Janowitz T, Baglenz E, Pattinson D, Wang TC, Conigliaro J. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalized patients: a case series. Gut 2020; 69:1592-1597.

150. Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized COVID-19 patients. Am J Gastroenterol 2020.

151. Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM. COVID-19: Famotidine, Histamine, Mast Cells, and mechanisms. Research Square 2020.

152. Sethia R, Prasad M, Mahapatra SJ, Nischal N, Soneja M. Efficacy of famotidine for COVID-19: A systematic review and meta-analysis. medRxiv 2020.

153. Shoaibi A, Fortin S, Weinstein R, Berlin JA. Comparative effectiveness of famotidine in hospitalized COVID-19 patients. medRxiv 2020.

154. Yeramaneni S, Doshi P, Sands K, Cooper M, Kurbegov D, Fromell G. Famotidine use is not associated with 30-day mortality: A coarsened exact match study in 7158 hospitalized COVID-19 patients from a large healthcare system. medRxiv 2020.

155. Jalali F, Rezaie S, Rola P, Kyle-Sidell C. COVID-19 pathophysiology: Are platelets and serotonin hiding in plain sight? ssrn 2021.

156. Lin OA, Karim ZA, Vemana HP, Espinosa EV, Khasawneh FT. The antidepressant 5-HT2a receptor antagonists Pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. PloS ONE 2014; 9:e87026.

157. Zaid Y, Guessous F, Puhm F, Elhamdani W, Chentoufi L, Morris AC. Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19. Blood Advances 2021; 5:635-639.

158. Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ Res 2020; 127:1404-1418.

159. Dawson C, Christensen CW, Rickaby DA, Linehan JH, Johnston MR. Lung damage and pulmonary uptake of serotonin in intact dogs. J Appl Physiol 1985; 58:1761-1766.

160. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and the relevance to pulmonary arterial hypertension. Br J Pharmacol 2000; 131:161-168.

161. Blackshear JL, Orlandi C, Hollenberg NK. Constrictive effect of serotonin on visible renal arteries: a pharmacoangiographic study in anesthetized dogs. J Cardiovasc Pharmacol 1991; 17:68-73.

162. Watchorn J, Hang DY, Joslin J, Bramham K, Hutchings SD. Critically ill COVID-19 patients with acute kidney injury have reduced renal blood flow and perfusion despite preserved cardiac function: A case-control study using contrast enhanced ultrasound. Lancet Resp Med 2021.

163. McGoon MD, Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 1984; 74:823-833.

164. Almqvist P, Skudder P, Kuenzig M, Schwartz SI. Effect of cyproheptadine on endotoxin-induced pulmonary platelet trapping. Am Surg 1984; 50:503-505.

165. Skurikhin EG, Andreeva TV, Khnelevskaya ES, Ermolaeva LA, Pershina OV, Krupin VA. Effect of antiserotonin drug on the development of lung fibrosis and blood system reactions after intratracheal administration of bleomycin. Bull Exp Biol Med 2012; 152:519-523.

166. Doaei S, Gholami S, Rastgoo S, Bourbour F, Ghorat F, Joola P. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. J Transl Med 2021; 19:128.

167. Spinelli FR, Conti F, Gadina M. HiJAKing SARS-C0V-2? The potential role of JAK inhibitors in the management of COVID-19. Sci Immunol 2020; 5:eabc5367.

168. Chen CX, Wang JJ, Li H, Yuan LT, Gale RP. JAK-inhibitors for coronavirus disease-2019 (COVID): a meta-analysis. Leukemia 2021.

169. Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V. Efficacy and safety of baricitinib for the treament of hospitalized adults with COVID-19 (COV-BARRIER): a randomised, double-blind,parallel-group, placebo-controlled phase 3 trial. Lancet Resp Med 2021.

170. Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM. Repurposed antiviral drugs for COVID-19 - interim WHO SOLIDARITY trial. medrx 2020.

171. Ohl ME, Miller DR, Lund BC, Kobayashi T, Miell KR. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19. JAMA Network Open 2021; 4:e2114741.

172. Ader F, Hites M, Poissy J, Belhadi D, Diallo A, Staub T. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 2021.

173. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Pollak U. Colchicine poisoning: the dark side of an acient drug. Clinical Toxicology 2010; 48:407-414.

174. Wimalawansa SJ. Rapidly increasing serum 25(OD)D boosts immune system, against infections - Sepsis and COVID-19. Nutrients 2022; 14:2997.

175. Ranjbar K, Shahriarad R, erfani A, Khodamoradi Z, Saadi MH. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalized COVID-19 patients: A triple-blinded randomized controlled trial. BMC Infect Dis 2021; 21:337.

176. Ko JJ, Wu C, Mehta N, Wald-Dickler N, Yang W. A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19. medRxiv 2021.

177. Fowler AA, Truwit JD, Hite D, Morris PE, DeWilde C, Priday A et al. Vitamin C Infusion for TReatment In Sepsis-Induced Acute Lung Injury- CITRIS-ALI: A Randomized, Placebo Controlled Clinical Trial. JAMA 2018; 322:1261-1270.

178. Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C and Thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study. Chest 2017; 151:1229-1238.

179. Marik PE. Vitamin C for the treatment of sepsis: The scientific rationale. Pharmacol Therapeut 2018; 189:63-70.

180. Cheng RZ. Can early and high-dose vitamin C prevent and treat coronavirus disease 2019 (COVID-19). Medicine in Drug Discovery 2020.

181. Wang Y, Lin H, Lin BW, Lin JD. Effects of different ascorbic acid doses on the mortality of critically ill patients: a meta-analysis. Ann Intensive Care 2019; 9:58.

182. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition 2020; 12:100190.

183. Iglesias J, Vassallo AV, Patel V, Sullivan JB, Cavanaugh J, Elbaga Y. Outcomes of metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in the early treatment of sepsis. Chest 2020; 158:164-173.

184. Hiedra R, Lo KB, Elbashabsheh M, Gul F, Wright RM. The use of IV vitamin C for patients with COVID-19: a case series. Exp Rev Anti Infect Ther 2020.

185. Zhang J, Rao X, Li Y, Zhu Y, Liu G, Guo G et al. High-dose vitamin C infusion for the treatment of critically ill COVID-19. Research Square 2020.

186. Kumari P, Dembra S, Dembra P, Bhawna F, Gul A, Ali B. The role of vitamin C as adjuvant therapy in COVID-19. Cureus 2020; 12:e11779.

187. Al Sulaiman K, Al Juhani O, Badreldin HA, Salah KB, Alharbi A, Arabi YM. Adjunctive therapy with ascorbic in critically ill patients with COVID-19: A multicenter propensity score matched study. Crit Care 2021.

188. Lankadeva YR, Peiris RM, Okazaki N, Birchall IE, Doenom A, Evans RG et al. Reversal of the pathophysiological responses to Gram-negative sepsis by megadose Vitamin C. Crit Care Med 2020.

189. Zhang J, Rao X, Li Y, Zhu Y, Liu G, Guo G et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intenisve Care 2020.

190. Lavinio A, Ercole A, Battaglini D, Magnoni S, Badenes R, Thomas W et al. Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units. Crit Care 2021; 25:155.

191. Patterson G, Isales CM, Fulzele S. Low level of vitamin C and dysregulation of vitamin C transporter might be involved in the severity of COVID-19 infection. Aging and Disease 2020; 12.

192. Tomassa-Irriguible TM, Lielsa-Berrocal L. COVID-19: Up to 87% critically ill patients had low vitamin C values. Research Square 2020.

193. Arvinte C, Singh M, Marik PE. Serum levels of vitamin C and vitamin D in a cohort of critically ill COVID-19 patients of a North American Community Hospital Intensive Care Unit in May 2020. A pilot study. Medicine in Drug Discovery 2020; 8:100064.

194. Lopes RD, Furtado RH, Bronhara B, Damiani LP, Barbosa LM. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentraion (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397:2253-2263.

195. Kalfas S, Visvanathan K, Chan K, Drago J. The therapeutic potential of ivermectin for COVID-19: A systematic review of mechanisms and evidence. medRxiv 2020.

196. Menezes RR, Godin AM, Rodrigues FF, Coura GM, Melo IS, Brito AM. Thiamine and riboflavin inhibit production of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic model of inflammation induced by complete Freund's adjuvant. Pharmacological Reports 2020; 69:1036-1043.

197. Vatsalya V, Li F, Frimodig J, Gala KS, Srivastava S, Kong M. Therapeutic prospects for Th-17 cell immune storm syndrome and neurological symptoms in COVID-19: Thiamine efficacy and safety, In-vitro evidence and pharmacokinetic profile. medRxiv 2020.

198. Mallat J, Lemyze M, Thevenin D. Do not forget to give thiamine to your septic shock patient! J Thorac Dis 2016; 8:1062-1066.

199. Moskowitz A, Donnino MW. Thiamine (vitamin B1) in septic shock: a targeted therapy. J Thorac Dis 2020; 12 (suppl 1):S78-S83.

200. Woolum JA, Abner EL, Kelly A, Thompson Bastin ML, Morris PE, Flannery AH. Effect of thiamine administration on lactate clearance and mortality in patients with septic shock. Crit Care Med 2018; 46:1747-1752.

201. Marik PE. Thiamine: An essential component of the metabolic resuscitation protocol. Crit Care Med 2018; 46:1869-1870.

202. Al Sulaiman K, Aljuhani O, Al Dossari M, Alshahrani A, Alharbi A. Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: A multicenter propensity score matched study. Research Square 2021.

203. Zarehoseinzade E, Allami A, Ahmadi M, Bijani B. Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial. Medical Journal of the Islamic Republic of Iran 2021; 35:30.

204. Chen L, Jiang X, Huang L, Lan K, Wang H, Hu L et al. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: A randomized sequence, open-label, two-way crossover study. Clinical Therapeutics 2009; 31:2242-2248.

205. Tan CW, Ho LP, Kalimuddin S, Cherng BP, Teh YE. Cohort study to evaluate effect of vitamin D, magnesium, and vitamin b12 in combination on severe outcome progression in older patients with coronavirus (COVID-19). Nutrition 2020; 80:111017.

206. Lee CY, Jan WC, Tsai PS, Huang CJ. Magnesium sulfate mitigates acute lung injury in endotoxemia rats. J Trauma 2011; 70:1177-1185.

207. Salem M, Kasinski N, Munoz R, Chernow B. Progressive magnesium deficiency inceases mortality from endotoxin challenge:Protective effects of acute magnesium replacement therapy [abstract]. Crit Care Med 1995;A260.

208. Jiang P. Does hypomagnesemia impact on the outcome of patients admitted to the intensive care unit? A systematic review and meta-analysis. Shock 2019; 47:288-295.

209. Duarte M, Pelorosso F, Nicolosi L, Salgado V, Vetulli H. Telmisartan for treatment of COVID-19 patients: an open multicenter randomized clinical trial. EClinicalMedicine 2021; 37:100962.

210. Rothlin RP, Vetulli HM, Duarte M, Pelorosso FG. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Drug Dev Res 2020; 81:768-770.

211. Nejat R, Sadr AS, Freitas BT, Murray J, Pegan SD. Losartan inhibits SARS-CoV-2 replication in vitro. J Pharm Pharm Sci 2021; 24:390-399.

212. Patterson BK, seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J et al. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and deceases SARS-CoV2 RNA in plasma by day 14. International Journal of Infectious Diseases 2021; 103:25-32.

213. Patterson BK, Guevara-Coto J, Yogendra R, Francisco E, Long E, Pise A. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol 2021.

214. Li S, Jiang L, Li X, Lin F, Wang Y, Li B. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight 2020; 5:e138070.

215. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnager T. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020; 371:m3939.

216. Simonovich VA, Pratx LD, Scibona P, Beruto MV, Vallone MG. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med 2020.

217. Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B, de Molina RM. Convalescent plasma for COVID-19: A multicenter, randomized clinical trial. medRxiv 2020.

218. Balcells ME, Rojas L, Le Corre N, Ceballos ME, Ferres M, Chang M. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLOS Med 2021; 18:e1003415.

219. Janiaud P, Axfors C, Schmitt AM, Glory V, Moher D. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19. A systematic review and meta-analysis. JAMA 2021.

220. Li L, Zhang W, Hu Y, Tong X, Zeng S, Yang J. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. A randomized clinical trial. JAMA 2020; 324:460-470.

221. Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria Jurnal 2003; 3 (Suppl I):S8.

222. Thompson MA, Henderson JP, Shah PK, Rubenstein SM, Joyner MJ, Flora DB. Convalescent plasma and improved survival in patients with hematologic malignancies and COVID-19. medRxiv 2021.

223. Westendorf K, Zentelis S, Wang L, Foster D, Wiggin M, Lovett E. LY-CoV1404 (bebtelovimab) potently neuralizes SARS-CoV-2 variants. bioRxiv 2022.

224. Rosas IO, Brau N, Waters M, Go R, Hunter BD, Bhagani S et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv 2020.

225. Hermine O, Mariette X, Tharaux PL, Resche-Rignon M, Porcher R. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized Clinical Trial. JAMA Intern Med 2020.

226. Stone JH, Frigault MJ, Sterling-Boyd NJ, Fernandes AD, Harvey FL. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020.

227. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Intern Med 2020.

228. Salama C, Han J, Yau L, Reiss WG, Kramer B. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2020.

229. Jeffreys L, Pennington SH, Duggan J, Breen A, Jinks J. Remdesivir-Ivermectin combination displays synergistic interactions with improved in vitro antiviral activity against SARS-CoV-2. bioRxiv 2020.

230. Gordon AC, Mouncey PR, Rowan KM, Nichol AD, Arabi YM, Annane D. Interleukin-6 receptor antagonists in critically ill patients with COVID-19 - Preliminary report. medRxiv 2021.

231. Bassetti M, Kollef MH, Timsit JF. Bacterial and fungal superinfections in critically ill patients with COVID-19. Intensive Care Med 2020.

232. Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clinical Microbiology & Infection 2021; 27:9-11.

233. Le Balc'h P, Pinceaux K, Pronier C, Seguin P, Reizine F. Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients. Crit Care 2020; 24:530.

234. Koehler P, Bassetti M, Chen SC, Colombo AL, Perfect JR. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021.

235. Ospina-Tascon GA, Calderon-Tapia LE, Garcia AF, Zarama V, Vargas MP, Vaaron J. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19. A randomized clinical trial. JAMA 2021; 326:2161-2171.

236. Xu Q, Wang T, Qin X, Zha L. Early awake prone position combined with high-flow nasal oxygen therapy in severe COVID-19; a case series. Crit Care 2020; 24:250.

237. Elharrar X, Trigui Y, Dois AM, Touchon F. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. JAMA 2020.

238. Reddy MP, Subramaniam A, Afroz A, Billah B, Lim ZJ, Wong SN. Prone positioning of nonintubated patients with Coronavirus Disease 2019- A systematic review and meta-analysis. Crit Care Med 2021.

239. Xin Y, Martin K, Morais CC, Gerard SE, Abate N, Sidhu U et al. Diminishing efficacy of prone positioning with late application in evolving lung injury. Crit Care Med 2021.

240. Haymet A, Bassi GL, Fraser JF. Airborne spread of SARS-CoV-2 while using high-flow nasal cannula oxygen therapy: myth or reality. Intensive Care Med 2020; 46:2248-2251.

241. Winslow RL, Zhou J, Windle EF, Nur I, Lall R, Ji C. SARS-CoV-2 environmental contamination from hospitalized patients with COVID-19 receiving erosol-generating procedures. Thorax 2021.

242. Francone M, Lafrate F, Masci GM, Coco S, Cilia F, Manganaro L et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. European Radiology 2020; 30:6808-6817.

243. Parry AH, Wani AH, Shah NN, Yaseen M, Jehangir M. Chest CT features of coronavirus disease-19 (COVID-19) pnemonia: which findings on initial CT can predict an adverse short-term outcome? BJR Open 2020; 2:20200016.

244. Zhang J, Meng G, Li W, Shi B, Dong H, Su Z. Relationship of chest CT score with clinical characteristics of 108 patients hospitalized with COVID-19 in Wuhan, China. Respiratory Research 2020; 21:180.
245. Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q et al. Chest CT severity score: An imaging tool for assessing severe COVID-19. Radiology: Cardiothoracic Imaging 2020; 2:e2000047.
246. Li K, Wu J, Wu F, Guo D, Cen L, Fang Z et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Investigative Radiology 2020; 55:1-5.
247. Pan F, Ye T, Sun P, Gui S, Liang B, Li L. Time course of lung changes at Chest CT during recovery from Coronavirus Disease 2019 (COVID-19). Radiology 2021; 295:715-721.
248. Ding X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. European Journal of Radiology 2020; 127:109009.
249. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N et al. Chest CT findings in Coronavirus disease 2019 (COVID-19): relationship to duration of infection. Radiology 2020; 295:685-691.
250. Ichikado K, Suga M, Muranka H, Gushima Y, Miyakawa H. Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: Validation in 44 cases. Radiology 2006; 238:321-329.
251. Ichikado K, Suga M, Muller NL, Tangiguchi H, Kondoh Y, akira M. Acute interstitial pneumonia. Comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med 2002; 165:1551-1556.
252. Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care 2020; 24:128.
253. Keith P, Wells AH, Hodges J, Fast SH. The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: A single center experience. Crit Care 2020; 24:518.
254. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002; 28:1434-1439.
255. Morath C, Weigand MA, Zeier M, Speer C, Tiwari-Heckler S. Plasma exchange in critically ill COVID-19 patients. Crit Care 2020; 24:481.
256. Khamis F, Al-Zakwani I, Al Hashmi S, Al Dowaiki S, Al Bahrani M. Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect DIs 2020; 99:214-218.
257. Fernandez J, Gratacos-Gines J, Olivas P, Costa M, Nieto S, Mateo D. Plasma exchange: An effective rescue therapy in critically ill patients with Coronavirus Disease 2019 infection. Crit Care Med 2020.
258. Gucyetmez B, Atalan HK, Sertdemir I, Cakir U, Telci L. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study. Crit Care 2020; 24:492.
259. Poor HD, Ventetuolo CE, Tolbert T, Chun G, Serrao G. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfuncion responsive to thrombolysis. medRxiv 2020.
260. Wang J, Najizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA. Tissue plasminogen activator (tPA) treatment for COVID-19 associated respiratory distress syndrome (ARDS): A case series. J Thromb Haemost 2020.

261. Abou-Arab O, Huette P, Debouvries F, Dupont H, Jounieaux V. Inhaled nitric oxide for critically ill Covid-19 patients: a prospective study. Crit Care 2020; 24:645.

262. Bagate F, Tuffet S, Masi P, Perier F, Razazi K. Rescue thearpy with inhaled nitric oxide and almitrine in COVID-19 patients with severe acute respiratory distress syndrome. Ann Intensive Care 2020.

263. Caplan M, Goutay J, Bignon A, Jaillette E, Favory R. Almitrine infusion in severe acute respiratory syndrome coronavirus-2 indued acute respiratory distress syndrome: A single-center observational study. Crit Care Med 2020.

264. Payen D. Coronavirus disease 2019 acute respiratory failure: Almitrine drug resuscitaion or resuscitating patients by almitrine? Crit Care Med 2020.

265. Henry MB, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. J Crit Care 2020; 58:27-28.

266. Abrams D, Lorusso R, Vincent JL, Brodie D. ECMO during the COVID-19 pandemic: when is it unjustified. Crit Care 2020; 24:507.

267. Supady A, Taccone FS, Lepper PM, Ziegeler S, Staudacher DL. Survival after extracorporeal membrane oxygenation in severe COVID-19 ARDS: results from an international multicenter registry. Crit Care Med 2021; 25:90.

268. Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020.

269. Cypel M, Keshavjee S. When to consider lung transplantation for COVID-19. Lancet Resp Med 2021; 8:944-946.

270. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med 2020.

271. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal interface. Annu Rev Immunol 2011; 29:273-293.

272. Jacobs JJ. Neutralizing antibodies mediate virus-immue pathology of COVID-19. Med Hypotheses 2020; 143:109884.

273. Seifirad S. Pirfenidone: A novel hypothetical treatment for COVID-19. Medical Hypotheses 2020; 144:11005.

274. Saba A, Vaidya PJ, Chavhan VB, Achlerkar A, Leuppi J. Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary firbosis. Sarcoidosis Vasc Diffuse Lung Dis 2018; 35:85-90.

275. Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa GD. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Resp Med 2020; 8:750-752.

276. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antibibrotic therapy. Lancet Resp Med 2020; 8:807-815.

277. Brouwer WP, Duran S, Kuijper M, Inc C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care 2019; 23:317.

278. Villa G, Romagnoli S, De Rosa S, Greco M, Resta M. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study. Crit Care 2020; 24:605.

279. Ahmad Q, DePerrior SE, Dodani S, Edwards JF, Marik PE. Role of inflammatory biomarkers in the prediction of ICU admission and mortality in patients with COVID-19. Medical Research Archives 2020; 8:1-10.
280. Marik PE, Stephenson E. The ability of procalcitonin, lactate, white blood cell count and neutrophil-lymphocyte count ratio to predict blood stream infection. Analysis of a large database. J Crit Care 2020; 60:135-139.
281. Ichikado K, Muranaka H, Gushima Y, Kotani T, Nader HM, Fujimoto K et al. Fibroproliferative changes on high-resolution CT in the acute respiratory distress syndrome predict mortality and ventilator dependency: a prospective observational cohort study. BMJ Open 2012; 2:e000545.
282. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol 2020; 92:856-862.
283. Howell AP, Parrett JL, Malcom DR. Impact of high-dose intravenous vitamin C for treatment of sepsis on point-of-care blood glucose readings. J Diabetes Sci Technol 2019.
284. Stephenson E, Hooper MH, Marik PE. Vitamin C and Point of Care glucose measurements: A retrospective, Observational study [Abstract]. Chest 2018; 154 (suppl.):255a.
285. Hekimian G, Kerneis M, Zeitouni M, Cohen-Aubart F, Chommeloux J. COVID-19 acute myocarditis and multisystem inflanmmatory syndrome in Adult Intensive and cardiac Care Units. Chest 2020.
286. Ma KL, Liu ZH, Cao CF, Liu MK, Liao J. COVID-19 myocarditis and severity factors: An adult cohort study. medRxiv 2020.
287. Brosnahan SB, Bhatt A, Berger JS, Yuriditsky E, Iturrate E. COVID-19 pneumonia hospitalizations followed by re-presentation for presumed thrombotic event. Chest 2020.
288. Giannis D, allen SL, Tsang J, Flint S, Pinhasov T, Williams S. Post-discharge thromboembolic outcomes and mortality of hospitalized COVID-19 patients: The CORE-19 registry. Blood 2021.
289. Spyropoulos AC, Lipardi C, Xu J, Peluso C, Spiro TE. Modified IMPROVE VTE Risk Score and elevated D-Dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH Open 2020; 4:e59-e65.
290. Kunutsor SK, Seidu S, Blom AW, Khunti K. Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence. Eur J Epidemiol 2017; 32:657-667.